Florida cancer specialists and the research institute define

Fort Myers, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) — An in-depth article by pharmacy experts from the Florida Cancer Specialists & Research Institute, LLC (FCS) published in issues of the American Journal of Managed Care® (AJMC ®) a call to action for the development of improved metrics to help reduce costs and better assess the performance of pharmacies that dispense oral oncolytic drugs. Titled “Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies,” the authors detail proven predictive markers for successfully managing the care of cancer patients who have been prescribed these specialty drugs.

Oral oncolytics today play a major role in the treatment of patients with many types of cancers, offering clinical advantages and patient conveniences over intravenously administered drugs. These new therapies play a key role in transforming an increasing number of cancers into chronic diseases, allowing patients to live longer with good care. To fully benefit from the long-term use of these expensive therapies, a high level of support from pharmacists, pharmacy technicians and other oncology specialists is required.

FCS Senior Vice President of Pharmaceutical Services for Rx To Go Ray Bailey, BPharm, RPh, said, “Through our proven, multi-faceted approach, we help patients access therapies, ensure timely delivery, provide one-on-one education, stay in constant communication to ensure medication adherence, and effectively reduce costs for patients and payers. »

“Data from our implementation of quality performance dashboards, workflow strategies, and patient and provider satisfaction surveys demonstrates the value of our approach,” said Natasha Khrystolubova, RPh, BPharm, BCOP, FCS Director of Pharmacy Clinical Services for Rx To Go.

However, due to outdated practices of Pharmacy Benefit Managers (PBMs), Medicare patients, in particular, frequently encounter barriers to drug access as well as increased out-of-pocket costs that accelerate their entry into coverage gaps. . In addition, specialty pharmacy providers do not receive adequate reimbursement.

The authors state, “More discussion and collaboration among all stakeholders is needed to develop a set of metrics applicable to in-house and other specialty pharmacies that dispense oral oncolytics.

“Medically integrated oncology pharmacies such as FCS’s in-house specialty pharmacy, Rx To Go, provide the expertise and patient-centered support that are critical to achieving optimal outcomes,” said FCS Chief Executive Officer, Nathan H. Walcker. “The predictive markers of success we have identified through our leadership role in value-based cancer care can be used to effectively reduce costs for patients and providers and positively impact care outcomes against cancer. the cancer.

Lucio Gordan, MD, FCS Chief Medical Officer of Therapeutics & Analytics, said, “We call on pharmacy benefit managers, plan sponsors and the Pharmacy Quality Alliance to work with the broader oncology pharmacy community to develop measures specific performance measures structured to reward, not penalize, the best performing pharmacies.

The article, prepared with financial assistance from the Community Oncology Alliance (COA), was co-authored by the following FCS individuals: Lucio Gordan, MD, Medical Director of Therapeutics & Analytics, Ray Bailey, BPharm, RPh, Senior Vice President of Pharmacy Services, Natasha Khrystolubova, RPh, BPharm, BCOP, Director of Clinical Pharmacy Services, Roger Orr, PharmD, BCOP, Associate Director, Clinical Pharmacy Services and Trista Auger, RPhT, CPhT, Results Assistant health.

See main article: https://www.ajmc.com/view/defining-appropriate-quality-performance-metrics-for-pharmacies-dispensing-oral-oncology-therapies

View call to action: https://www.ajmc.com/view/a-call-to-action-oncology-practices-and-patients-need-performance-measures-for-managing-oral-therapies

# # #

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)

Recognized by the American Society of Clinical Oncology (ASCO) with a National Clinical Trial Participation Award, Florida Cancer Specialists & Research Institute (FCS) provides patients with access to more clinical trials than any medical practice. private oncology in Florida. The majority of new cancer drugs recently approved for use in the United States have been studied in clinical trials with the participation of Florida cancer specialists.

Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional, compassionate patient care driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, treatments based on genomics and immunotherapy. Our highest values ​​are embodied by our exceptional team of highly qualified and dedicated physicians, clinicians and staff.

*Before approval

  • To fully benefit from the long-term use of these expensive therapies, a high level of support from pharmacists, pharmacy technicians and other oncology specialists is required.


        

Comments are closed.